Editing Of Human Embryo Genes Raises Ethics Questions
By Britt E. Erickson,
Chemical & Engineering News
| 06. 29. 2015
Untitled Document
A little more than a decade after scientists first unraveled the human genome, some researchers are trying to rewrite it. Advances in gene-editing technology have provided relatively inexpensive and easy ways to delete, insert, or replace genes in human cells to correct defects associated with devastating diseases such as cystic fibrosis and sickle cell anemia. Gene-editing tools could also be used to alter plant and animal genomes to boost agricultural yields and food production or to modify insect genomes to reduce the spread of diseases such as malaria.
Not only are gene-editing tools scientifically promising, they also have the potential to be highly lucrative commercially. But with that promise comes worries that gene-editing technology could be used to create designer babies with enhanced traits, such as higher intelligence or greater beauty. Many scientists are also worried that the technology could change the human germ line—the DNA in reproductive cells that is passed on from one generation to the next—in unexpected or dangerous ways.
The ethical implications and risks of human gene editing came to a head in April...
Related Articles
By Jenny Kleeman, The Guardian | 05.30.2026
On a Friday evening in late April, Cathy Tie, the Canadian serial entrepreneur and self-styled “Biotech Barbie”, is centre stage at New York City’s famous Carnegie Hall, performing Saint-Saens’ Piano Concerto No 2 on a gleaming Steinway grand piano, accompanied...
By Virginia Heffernan, The New Republic | 05.29.2026
Here and there, it’s been a good month for humanity—or “magnificas humanitas,” as Pope Leo XIV calls us poor featherless bipeds.
On May 25, the pope published his encyclical letter “on safeguarding the human person in the time of artificial...
By Rebecca Roberts, The Scientist | 05.19.2026
Scientists have had prenatal gene therapy in their sights for decades; by treating the fetus in utero, they can potentially prevent the long-term damage caused by severe, early-onset genetic disorders. Despite its success in preclinical studies, the method has...
By Moe Alsumidaie, The Clinical Trial Vanguard | 05.26.2026
Picture the moment a gene therapy trial’s safety monitor pulls up a patient record — years after the last dose, long after the trial team has dissolved and the CRO contract has closed — and finds a tumor. The vector...
